Cartesian Therapeutics
RNAC
56 hedge funds and large institutions have $52.6M invested in Cartesian Therapeutics in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 9 closing their positions.
145% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 11
88% more capital invested
Capital invested by funds: $28M → $52.6M (+$24.6M)
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
4% more funds holding
Funds holding: 54 → 56 (+2)
0.1% more ownership
Funds ownership: 1.56% → 1.66% (+0.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
70% less call options, than puts
Call options by funds: $9K | Put options by funds: $30K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$6.58M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$5.94M |
| 3 |
AG
Artal Group
Luxembourg
|
+$3.17M |
| 4 |
O
OrbiMed
New York
|
+$2.75M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$1.6M |
| 2 |
JP Morgan Chase
New York
|
-$1.04M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$658K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$221K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$179K |
RNAC Hedge Fund Activity: Q1 2019 in Review
56 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q1 2019, worth a combined $52.6M — up 88% from $28M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RNAC positions and 9 closed out — a net gain of 2 holders — while 27 added to existing stakes and 11 trimmed.
The largest buyer was Man Group, adding an estimated $6.58M. The largest seller was Kennedy Capital Management, exiting entirely with an estimated $1.6M sold.
- 56 institutional investors held Cartesian Therapeutics (RNAC) as of Q1 2019, up from 54 in Q4 2018.
- Funds reported $52.6M of Cartesian Therapeutics stock for Q1 2019, up 88% quarter-over-quarter.
- 11 funds opened new Cartesian Therapeutics positions in Q1 2019 and 9 closed out, a net change of +2 holders.
- The largest Cartesian Therapeutics buyer in Q1 2019 was Man Group, an estimated $6.58M added.
- The largest Cartesian Therapeutics seller in Q1 2019 was Kennedy Capital Management, an estimated $1.6M sold.
Based on aggregated 13F filings for Q1 2019.